Pharmacologic and genetic perturbations across gastrointestinal and colitis-associated models demonstrate that CXCR2 signaling governs granulocytic recruitment and tumor promotion, providing mechanistic support for therapeutic targeting of this pathway (28, 29). This evidence concerns the gene CXCR2 and neoplasm.